Head-To-Head Comparison: Moleculin Biotech (NASDAQ:MBRX) versus Biora Therapeutics (NASDAQ:BIOR)

Biora Therapeutics (NASDAQ:BIOR) and Moleculin Biotech (NASDAQ:MBRX) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, risk, institutional ownership, dividends, profitability, earnings and valuation.

Volatility and Risk

Biora Therapeutics has a beta of 1.12, suggesting that its share price is 12% more volatile than the S&P 500. Comparatively, Moleculin Biotech has a beta of 1.94, suggesting that its share price is 94% more volatile than the S&P 500.

Valuation and Earnings

This table compares Biora Therapeutics and Moleculin Biotech”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biora Therapeutics	$892,000.00	0.90	-$124.11 million	($13.04)	-0.01
Moleculin Biotech	N/A	N/A	-$29.77 million	N/A	N/A

Moleculin Biotech has lower revenue, but higher earnings than Biora Therapeutics.

Profitability

This table compares Biora Therapeutics and Moleculin Biotech’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Biora Therapeutics	N/A	N/A	-332.47%
Moleculin Biotech	N/A	-157.44%	-97.16%

Analyst Ratings

This is a summary of recent ratings and target prices for Biora Therapeutics and Moleculin Biotech, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biora Therapeutics	0	0	1	0	3.00
Moleculin Biotech	0	0	2	0	3.00

Biora Therapeutics presently has a consensus price target of $23.00, indicating a potential upside of 12,814.09%. Moleculin Biotech has a consensus price target of $24.00, indicating a potential upside of 1,311.76%. Given Biora Therapeutics’ higher probable upside, equities analysts clearly believe Biora Therapeutics is more favorable than Moleculin Biotech.

Insider and Institutional Ownership

43.7% of Biora Therapeutics shares are owned by institutional investors. Comparatively, 15.5% of Moleculin Biotech shares are owned by institutional investors. 51.1% of Biora Therapeutics shares are owned by company insiders. Comparatively, 7.1% of Moleculin Biotech shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Biora Therapeutics beats Moleculin Biotech on 5 of the 9 factors compared between the two stocks.

About Biora Therapeutics

Biora Therapeutics, Inc., a clinical-stage biotechnology company, engages in developing oral biotherapeutics in the United States. The company offers NaviCap, a targeted oral delivery platform for delivery of therapeutics in the gastrointestinal tract to enhance the treatment of inflammatory bowel diseases; and BioJet, a systemic oral delivery platform designs to replace injection with needle-free, oral delivery of large molecules for management of chronic diseases. The company was formerly known as Progenity, Inc. and changed its name to Biora Therapeutics, Inc. in April 2022 to reflect its focus on its therapeutics pipeline. Biora Therapeutics, Inc. was founded in 2010 and is headquartered in San Diego, California.

About Moleculin Biotech

Moleculin Biotech, Inc., a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma metastasized to the lungs. The company is also developing WP1066, an immune/transcription modulator designed to inhibit phosphorylated signal transducer and activator of transcription and other oncogenic transcription factors targeting brain tumors, and pancreatic and other cancers. In addition, it develops WP1220, an analog of WP1066 for the topical treatment of cutaneous T-cell lymphoma; and WP1122 to treat viruses, as well as cancer indications, including brain tumors, and pancreatic and other cancers. The company was incorporated in 2015 and is headquartered in Houston, Texas.